Group One Trading’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-50,000
| Closed | -$117K | – | 8386 |
|
|
2022
Q3 | $117K | Buy |
+50,000
| New | +$177K | ﹤0.01% | 4636 |
|
|
2022
Q2 | – | Sell |
-5,600
| Closed | -$38K | – | 8800 |
|
|
2022
Q1 | $38K | Buy |
5,600
+5,500
| +5,500% | +$39.2K | ﹤0.01% | 6326 |
|
|
2021
Q4 | $1K | Buy |
+100
| New | +$824 | ﹤0.01% | 8080 |
|
|
2021
Q3 | – | Sell |
-200
| Closed | -$1K | – | 8993 |
|
|
2021
Q2 | $1K | Sell |
200
-300
| -60% | -$2.49K | ﹤0.01% | 8052 |
|
|
2021
Q1 | $5K | Sell |
500
-30,100
| -98% | -$330K | ﹤0.01% | 7264 |
|
|
2020
Q4 | $214K | Sell |
30,600
-300
| -1% | -$2.33K | ﹤0.01% | 4007 |
|
|
2020
Q3 | $252K | Buy |
30,900
+28,900
| +1,445% | +$179K | ﹤0.01% | 3472 |
|
|
2020
Q2 | $14K | Sell |
2,000
-5,400
| -73% | -$29.1K | ﹤0.01% | 5012 |
|
|
2020
Q1 | $35K | Sell |
7,400
-18,500
| -71% | -$106K | ﹤0.01% | 3945 |
|
|
2019
Q4 | $226K | Buy |
+25,900
| New | +$140K | ﹤0.01% | 3087 |
|
|
2018
Q4 | – | Sell |
-20,300
| Closed | -$132K | – | 5587 |
|
|
2018
Q3 | $132K | Sell |
20,300
-17,200
| -46% | -$128K | ﹤0.01% | 3328 |
|
|
2018
Q2 | $287K | Buy |
37,500
+34,500
| +1,150% | +$498K | ﹤0.01% | 2754 |
|
|
2018
Q1 | $67K | Buy |
+3,000
| New | +$66.6K | ﹤0.01% | 3502 |
|
Other funds holding JNCE
Group One Trading's JNCE Position: Q4 2022 in Review
Group One Trading sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 2,334 shares — an estimated $5K sold.
Group One Trading first reported a position in JNCE in Q4 2017 and held it in 15 quarters. The position peaked at $276K in Q3 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.
- Group One Trading reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Group One Trading sold 2,334 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $5K.
- Group One Trading first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
- Group One Trading's Jounce Therapeutics, Inc. Common Stock position peaked at $276K in Q3 2018.
- 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.